Cogent Biosciences (COGT) Long-Term Investments (2023 - 2024)
Cogent Biosciences (COGT) posted quarterly Long-Term Investments of $10.0 million for Q3 2024, down 70.32% year-over-year from $33.8 million in Q4 2023, and down 62.42% quarter-over-quarter from $26.7 million in Q2 2024.
Powered by 
Analysis
Cogent Biosciences (COGT) Long-Term Investments (2023 - 2024) Analysis & Trends
Cogent Biosciences (COGT) has reported Long-Term Investments for 2 consecutive years, with $10.0 million the latest figure, recorded in Q3 2024.
- In Q3 2024, Long-Term Investments fell 70.32% year-over-year to $10.0 million; the TTM figure through Sep 2024 stood at $10.0 million (down 70.32% YoY), while the FY2023 annual figure was $7.5 million, changed N/A from the prior year.
- Long-Term Investments slipped to $10.0 million in Q3 2024 per COGT's latest filing, from $26.7 million in the prior quarter.
- Across five years, Long-Term Investments topped out at $33.8 million in Q3 2023 and bottomed at $7.5 million in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -4.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 1.77 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.17 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 372.10 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Cogent Biosciences | 5.94 Bn | 5.94 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2024 | 10.03 Mn |
| Jun 30, 2024 | 26.69 Mn |
| Dec 31, 2023 | 7.46 Mn |
| Sep 30, 2023 | 33.79 Mn |
| Jun 30, 2023 | 21.51 Mn |